Addex and the Charcot-Marie-Tooth Association enter collaboration to advance ADX71441 in Charcot-Marie-Tooth 1A disorder

Addex Therapeutics Reports First Half 2014 Financial Results

Addex ADX71441 Positive Results in Preclinical Model of Nicotine Addiction

Addex Shareholders Approve All Board Proposals at Annual General Meeting

Addex Therapeutics Publishes Annual General Meeting Agenda

Addex Therapeutics Publishes Annual Report 2013

Addex Therapeutics Reports 2013 Financial Results

Addex Reports Top-line Data from ADX71149 Phase 2a Study in Patients with Major Depressive Disorder (MDD) with Significant Anxiety Symptoms

Addex and NIDA enter collaboration to advance ADX71441 & ADX88178 in drug abuse and addiction

Addex Licensee Completes Enrolment of 120 Patients in a Phase 2 Clinical Trial of ADX71149 for the Treatment of Anxious Depression